Health
Neutrolis announces development of first-in-class therapy to target NETs in COVID-19 patients – News-Medical.Net
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemica…
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.
We believe NETs are the common factor that explains the …
-
Noosa News17 hours agoFirst home buyers’ options to almost double under expanded Home Guarantee Scheme
-
Business21 hours agoBrokers name 3 quality ASX 200 shares to buy today
-
Business19 hours agoMorgans says these ASX shares could rise 30%+
-
General23 hours agoExplosions heard in Qatar capital Doha, Israel announces strike on Hamas ‘senior leadership’